2nd Vaccine Research and Innovation Conference
11th July 2012 — 12th July 2012

Investigation of vaccine delivery systems, vaccine targets and improved production methods 11th - 12th July 2012, London EC1, UK

Vaccines and future developments in vaccine delivery technology will change how we prevent and treat disease. They open up a whole new scope to target non-infectious disease and not just through traditional vaccine targets. The possibility to treat chronic disease such as diabetes, cancer, Alzheimer's and addiction is currently being investigated.

New routes of vaccine delivery will not only encourage patient compliance but will also allow the vaccination of more underprivileged populations where transport and supply chain issues restrict delivery. They can help to overcome barriers such as a hot climate and needle disposal in countries which do not have the resources to effectively destroy the tools used in administering current vaccines.

In 2011 the market had 26 diseases that were capable of being prevented by vaccines. So far the existing market can be categorised into the following groups: Paediatric vaccines, Influenza vaccines and other prophylactic and therapeutic vaccines. Influenza vaccines dominated the stage in 2010 due to pandemic scares, however the market is now favouring therapeutic vaccines with advancements in these areas expected to grow rapidly. In 2010 the total revenues were $27.5bn; these revenues are predicted to grow through to 20211.

Children are the most vaccinated demographic and therefore paediatric vaccines are predicted to continue to dominate the market1, with well established vaccines being widely accepted by society. Influenza vaccines also dominate the market have an important and regular seasonal role however shortages of influenza vaccines occur. This can be attributed to the low-yielding traditional egg-based manufacturing technology1. As new substrates combat these traditional methods we see an increase in the effectiveness of production and supply to all demographics and countries alike.

As the market for vaccines and vaccine targets grow among chronic diseases and potential new areas of use, the demand for vaccines will rise. This will result in the outsourcing of vaccines to meet consumer demand and will only increase as more vaccines are introduced to developing countries, when barriers for supply such as cold chain issues are overcome. Vaccines are an established method of disease prevention, and with the move toward therapeutic vaccines this is an exciting and new frontier in the market.

Visiongain's Vaccine Research and Innovation event is a chance to review new research into the discovery and innovation of vaccine delivery systems, vaccine targets and production methods. This timely conference will provide a platform to discuss new ideas and integrate research while establishing a great networking opportunity.

1 Visiongain Report: World Vaccines Market 2011-2021

Why attend this event?
• Investigate new adjuvants
• Discover new cell lines used in the production of vaccines
• Manufacturing and purification strategies of conjugate vaccines
• Explore new target pathways for vaccines
• Explore new types of vaccines: recombinant live vaccines, inactivated vaccines, toxoid vaccines, subunit vaccines, conjugate vaccines, recombinant subunit vaccines, DNA vaccines and recombinant vector vaccines
• Discover if personalised vaccines are viable options
• Examine novel targets for cancer vaccine delivery
• Advancements in supply chain issues, particularly diversifying from the cold chain
• High-throughput stable cell line generation
• To outsource or not to outsource - what options are available and is it viable

Who should attend?

VPs, Directors, Heads, Managers of:
• Vaccine equipment and manufacturing
• Vaccine application development
• Vaccinology and molecular biology
• Cell line engineering
• Scientists
• Lyophilisation specialists
• Proteomics, recombinant protein/DNA biotechnology
• Infectious disease R&D
• In-licensing and out-licensing
• Pharmacovigilance and safety testing
• Regulatory affairs
• Strategic product development
• Manufacturing/production
• Chemistry manufacturing and controls (CMC)
• Procurement & purchasing
• Cold chain supply
• Strategic alliances
• Clinical product resourcing
• Supply outsourcing project management
• Contract management
• Process development
• Business development
• Drug discovery & delivery
• Patent law
• Investment and venture capital

Expected Number of Attendees

NA

View Conference Website: 2nd Vaccine Research and Innovation Conference

Price of Attendance

n/a

Brochure

View Event Brochure

Location

London
London
London
United Kingdom
London